Skip to main content

Table 3 Correlation between the clinicopathological characteristics and expression of ELF and TGF-β1 in the 84 HCC patients

From: The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma

Variables Cases ELF expression P value TGF-β1 expression P value
   Low High   Low High  
Age(yrs)        
 > = 60 16 7(43.8%) 9(56.2%) 0.442 9(54.4%) 7(54.4%) 0.325
 <60 68 37(54.4%) 31(45.6%) 29(42.6%) 39(57.4%)
Sex        
 Male 68 37(54.4%) 31(45.6%) 0.44 27(39.7%) 41(60.3%) 0.77
 Female 16 7(43.8%) 9(56.2%) 7(43.8%) 9(56.2%)
HCC family history        
 Yes 6 2(33.3%) 4(66.7%) 0.83 3(50.0%) 3(50.0%) 0.95
 No 78 42(53.8%) 36(46.2%) 31(39.7%) 47(60.3%)
HbsAg        
 Positive 72 41(56.9%) 31(43.1%) 0.04 29(40.3%) 43(59.7%) 0.93
 Negative 12 3(25.0%) 9(75.0%) 5(41.7%) 7(58.3%)
 ALT(U/L)        
 ≥80 9 3(33.3%) 6(66.7%) 0.39 1(11.1%) 8(88.9%) 0.12
 <80 75 41(54.7%) 34(45.3%) 33(44.0%) 42(56.0%)
 PLT(×109)        
 >100 74 41(55.4%) 33(44.6%) 0.24 28(37.8%) 46(62.2%) 0.32
 ≤100 10 3(30.0%) 7(70.0%) 6(60.0%) 4(40.0%)
Cirrhosis        
 Yes 64 32(50.0%) 32(50.0%) 0.43 27(42.2%) 37(57.8%) 0.57
 No 20 12(60.0%) 8(40.0%) 7(35.0%) 13(65.0%)
AFP(ug/L)        
 ≥20 48 28(58.3%) 20(41.7%) 0.21 19(39.6%) 29(60.4%) 0.85
 <20 36 16(44.4%) 20(55.6%) 15(41.7%) 21(58.3%)
Tumor size (cm)        
 ≥5 50 32(64.0%) 18(36.0%) 0.01 13(26.0%) 37(74.0%) 0.001
 <5 34 12(35.3%) 22(64.7%) 21(61.8%) 13(38.2%)
Tumor number        
 Single 62 26(41.9%) 36(58.1%) 0.001 31(50.0%) 31(50.0%) 0.003
 Multiple 22 18(81.8%) 4(18.2%) 3(13.6%) 19(86.4%)
Differentiation        
 I-II 62 31(50.0%) 31(50.0%) 0.46 27(43.5%) 35(56.5%) 0.34
 III-IV 22 13(59.1%) 9(40.9%) 7(31.8%) 15(68.2%)
TNM stage        
 I-II 55 24(43.6%) 31(56.4%) 0.03 29(52.7%) 26(47.3%) 0.002
 III-IV 29 20(69.0%) 9(31.0%) 5(17.2%) 24(82.8%)
PVTT        
 Yes 11 8(72.7%) 3(27.3%) 0.15 2(18.2%) 9(81.8%) 0.11
 No 73 36(49.3%) 37(50.7%) 32(43.8%) 41(56.2%)
Tumor encapsulation        
 Complete 64 30(46.9%) 34(53.1%) 0.07 29(45.3%) 35(54.7%) 0.11
 None 20 14(70.0%) 6(30.0%) 5(25.0%) 15(75.0%)
Recurrence        
 Yes 56 39(69.6%) 17(30.4%) <0.001 12(21.4%) 44(78.6%) <0.001
 No 28 5(17.9%) 23(82.1%) 22(78.6%) 6(21.4%)
Complication        
 No 73 41(56.2%) 32(43.8%) 0.07 31(42.5%) 42(57.5%) 0.34
 Yes 11 3(27.3%) 8(72.7%) 3(27.3%) 8(72.7%)
  1. AFP, Alpha-fetoprotein; HBsAg, hepatitis B surface antigen; PLT, platelet; PVTT, portal vein tumor thrombi.
\